Novo Nordisk Advances DKK 15 Billion Share Buyback as Treasury Stake Reaches 0.8%
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
An update from Novo Nordisk ( (NVO) ) is now available.
Novo Nordisk, the Danish healthcare group focused on chronic diseases such as diabetes, continued executing its previously announced share repurchase plans in early June 2026 as part of a broader capital return strategy. The company’s buybacks support capital structure management and may signal confidence in its long-term earnings and cash-generation profile to investors.
Under the programme launched on 6 May 2026, Novo Nordisk is repurchasing B shares for up to DKK 11.2 billion within a 6 May 2026 to 1 February 2027 window, as part of a wider DKK 15 billion buyback running from 4 February 2026. Between 1 and 4 June 2026, the company bought an additional 870,000 B shares, bringing cumulative purchases under the May programme to 4 million shares and total 2026 repurchases to 18.76 million B shares, while treasury holdings now represent 0.8% of share capital.
The most recent analyst rating on (NVO) stock is a Hold
with a $45.00 price target.
To see the full list of analyst forecasts on Novo Nordisk stock,
see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.
The score is driven primarily by strong underlying profitability and multi-year revenue growth, supported by an attractive valuation (low P/E and solid dividend). The main offsets are higher leverage and weaker recent free-cash-flow conversion, alongside neutral-to-weak technical positioning relative to key moving averages and KPI-indicated concentration/region volatility that can pressure near-term consistency.
To see Spark’s full report on NVO stock,
click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, specialising in treatments for serious chronic diseases with a heritage in diabetes care. The group employs about 68,800 people in 80 countries, markets its medicines in around 170 countries, and has its B shares listed on Nasdaq Copenhagen and ADRs listed on the New York Stock Exchange.
Average Trading Volume: 16,252,744
Technical Sentiment Signal: Sell
Current Market Cap: $194.5B
For a thorough assessment of NVO stock, go to TipRanks’ Stock Analysis page.
